Amir Ali Judaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amir Ali Judaki has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Elham Rismani
Molecular Medicine Department, Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran
2 shared publications - Massoud Vosough
Royan Institute for Stem Cell Biology and Technology, ACECR
2 shared publications - Moustapha Hassan
Experimental Cancer Medicine (ECM), Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
2 shared publications - Pedram Asadi Sarabi
Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
2 shared publications - Alireza Beheshti-Maal
Department of Regenerative Medicine Cell Science Research Center Royan Institute for Stem Cell Biology and Technology ACECR Tehran Iran acecr.ac.ir
1 shared publication - Amirhossein Farrokhzad
Department of Cellular and Molecular Biology, Faculty of Sciences and Advanced Technology in Biology, University of Science and Culture, Tehran, Iran, usc.ac.ir
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1) , e9547868
Noninvasive Biomarkers for Early Detection of Primary Sclerosing Cholangitis in Ulcerative Colitis
Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease strongly associated with ulcerative colitis (UC). Although uncommon, PSC‐associated ulcerative colitis (PSCUC) represents a distinct subtype of inflammatory bowel diseases characterized by a higher risk of colorectal and hepatobiliary cancers. Early diagnosis remains a challenging issue because of the lack of specific biomarkers. Bioinformatic analysis of Gene Expression Omnibus (GEO) datasets identified potential, specific, and noninvasive biomarkers via differential gene expression and functional enrichment. After processing the data, S100A8 and S100A12 were identified as candidate biomarkers for detecting PSC in patients with UC. S100A8 encodes one component of calprotectin, the S100A8/S100A9 heterodimer widely used as a marker of intestinal inflammation. These two genes are primarily involved in inflammation, immune responses, and leukocyte recruitment, making them potentially useful biomarkers for early detection in PSC in UC patients. These biomarkers offer potential implications for disease stratification and therapeutic targeting. Further validation in prospective clinical studies is warranted to confirm their diagnostic and prognostic utilities.
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1) , e9547868
Open AccessNoninvasive Biomarkers for Early Detection of Primary Sclerosing Cholangitis in Ulcerative Colitis
Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease strongly associated with ulcerative colitis (UC). Although uncommon, PSC‐associated ulcerative colitis (PSCUC) represents a distinct subtype of inflammatory bowel diseases characterized by a higher risk of colorectal and hepatobiliary cancers. Early diagnosis remains a challenging issue because of the lack of specific biomarkers. Bioinformatic analysis of Gene Expression Omnibus (GEO) datasets identified potential, specific, and noninvasive biomarkers via differential gene expression and functional enrichment. After processing the data, S100A8 and S100A12 were identified as candidate biomarkers for detecting PSC in patients with UC. S100A8 encodes one component of calprotectin, the S100A8/S100A9 heterodimer widely used as a marker of intestinal inflammation. These two genes are primarily involved in inflammation, immune responses, and leukocyte recruitment, making them potentially useful biomarkers for early detection in PSC in UC patients. These biomarkers offer potential implications for disease stratification and therapeutic targeting. Further validation in prospective clinical studies is warranted to confirm their diagnostic and prognostic utilities.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Genomics
- Vol. 2026 (1)
Extracellular Matrix–Associated Biomarkers for Hepatocellular Carcinoma: Insights From Machine Learning and Single‐Cell Analysis
The 5‐year overall survival rate for hepatocellular carcinoma (HCC) patients remains below 20%. Alterations in the extracellular matrix (ECM) are increasingly recognized as central drivers of HCC initiation and progression. This study applied a system biology framework integrating omics data and machine learning to analyze gene expression and regulatory networks in HCC using The Cancer Genome Atlas. Eight ECM‐associated genes ( CSPG4 , CD34 , C1orf35 , ESM1 , MAPT , PLXDC1 , STC2 , and THBS4 ) were identified as upregulated diagnostic biomarkers with strong discriminatory power. Among them, MAPT , PLXDC1 , and STC2 showed significant associations with poor overall survival, defining a prognostic subset. Validation in the GSE104310 and GSE144269 datasets confirmed consistent expression patterns across cohorts. Functional enrichment linked these genes to tissue remodeling and angiogenesis. Single‐cell RNA sequencing revealed MAPT upregulation in T cells, PLXDC1 enrichment in cancer‐associated fibroblasts, and mild STC2 elevation in tumor‐associated macrophages and endothelial cells. These findings identify key ECM‐based biomarkers with potential for early detection, prognosis, and therapeutic targeting in HCC.
- 1 January 2026
- Published by Wiley in International Journal of Genomics
- Vol. 2026 (1)
Open AccessExtracellular Matrix–Associated Biomarkers for Hepatocellular Carcinoma: Insights From Machine Learning and Single‐Cell Analysis
The 5‐year overall survival rate for hepatocellular carcinoma (HCC) patients remains below 20%. Alterations in the extracellular matrix (ECM) are increasingly recognized as central drivers of HCC initiation and progression. This study applied a system biology framework integrating omics data and machine learning to analyze gene expression and regulatory networks in HCC using The Cancer Genome Atlas. Eight ECM‐associated genes ( CSPG4 , CD34 , C1orf35 , ESM1 , MAPT , PLXDC1 , STC2 , and THBS4 ) were identified as upregulated diagnostic biomarkers with strong discriminatory power. Among them, MAPT , PLXDC1 , and STC2 showed significant associations with poor overall survival, defining a prognostic subset. Validation in the GSE104310 and GSE144269 datasets confirmed consistent expression patterns across cohorts. Functional enrichment linked these genes to tissue remodeling and angiogenesis. Single‐cell RNA sequencing revealed MAPT upregulation in T cells, PLXDC1 enrichment in cancer‐associated fibroblasts, and mild STC2 elevation in tumor‐associated macrophages and endothelial cells. These findings identify key ECM‐based biomarkers with potential for early detection, prognosis, and therapeutic targeting in HCC.